静脉-动脉体外膜氧合治疗重度磷化铝中毒的真实世界经验
该单中心回顾性研究分析了2019至2023年间收治的182例磷化铝中毒患者,其中78例(42.9%)接受了静脉-动脉体外膜氧合,平均年龄34.4±11.7岁。启动体外膜氧合时76.9%存在多器官功能障碍、94.9%有心电图异常;87.2%在急诊科启动、10.3%在心肺复苏期间启动。体外膜氧合总生存率为67.9%(53例),32.1%(25例)死亡;17例可追踪的拒绝入院患者死亡率为100%。体外膜氧合相关并发症发生于80.8%的患者,其中19.2%为严重不良事件。作者认为体外膜氧合可在可逆性心肌抑制期间提供临时循环支持,但并发症风险高,需进一步前瞻性多中心研究。
要点
- 78例重度磷化铝中毒患者接受静脉-动脉体外膜氧合,总生存率67.9%(53/78),32.1%(25例)死亡。
- 体外膜氧合启动时76.9%(60例)存在多器官功能障碍,94.9%(74例)有心电图异常。
- 87.2%(68例)在急诊科启动体外膜氧合,10.3%(8例)在心肺复苏期间启动;从到达急诊至启动的中位时间为1小时(IQR 0.5-2.0小时),生存者中存在显著延迟(P=0.02)。
- 体外膜氧合相关并发症发生于80.8%(63例),其中19.2%(15例)为严重不良事件。
- 17例可追踪的拒绝入院患者死亡率为100%。
适用人群与场景
- 2019至2023年间单中心收治的磷化铝中毒患者,共182例入院,其中78例接受静脉-动脉体外膜氧合。
- 接受体外膜氧合者平均年龄34.4±11.7岁。
- 研究另追踪了17例拒绝入院的可追踪患者。
处置流程与药物剂量
- 静脉-动脉体外膜氧合在急诊科启动(68例,87.2%)或在心肺复苏期间启动(8例,10.3%)。
- 53例(67.9%)同时接受肾脏替代治疗。
- 体外膜氧合支持中位持续时间48.0小时(IQR 36.0-68.0小时),重症监护室中位停留6天(IQR 4-9天)。
研究设计与关键结果
- 研究类型为单中心回顾性研究,纳入2019至2023年182例磷化铝中毒入院患者,其中78例(42.9%)接受静脉-动脉体外膜氧合。
- 体外膜氧合患者总生存率为67.9%(53例),死亡25例(32.1%)。
- 从到达急诊至体外膜氧合启动的中位时间为1小时(IQR 0.5-2.0小时),生存者中存在显著延迟(P=0.02)。
- 体外膜氧合相关并发症发生于63例(80.8%),其中15例(19.2%)为严重不良事件。
- 17例可追踪的拒绝入院患者死亡率为100%。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 局限:单中心回顾性研究,限制研究结果的普适性,数据易受选择偏倚影响。
- 作者结论:需进一步前瞻性多中心研究以完善适应证、评估成本效益和长期结局。
对床旁实践的改变
- 作者认为静脉-动脉体外膜氧合可在可逆性心肌抑制期间提供临时循环支持,但并发症风险高。
- 作者建议需进一步前瞻性多中心研究以完善适应证、评估成本效益和评估长期结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Mitochondrial toxicity caused by phosphine released from aluminium phosphide in the presence of moisture leads to haemodynamic collapse, and the mortality from aluminium phosphide ingestion is high. In anecdotal studies, veno-arterial extracorporeal membrane oxygenation appears to reduce mortality.
METHODS: A retrospective, single-centre study was conducted of patients with aluminium phosphide poisoning managed between 2019 and 2023. Clinical data were retrieved and analysed. Additionally, outcomes of patients who declined hospital admission were traced and reviewed.
RESULTS: Of the 182 patients admitted with aluminium phosphide poisoning, 78 (42.9%) underwent veno-arterial extracorporeal-membrane-oxygenation, with a mean age of 34.4 ± 11.7 years. At presentation, 60 patients (76.9%) exhibited multiple organ dysfunction, and 74 (94.9%) showed electrocardiographic abnormalities. Veno-arterial extracorporeal membrane oxygenation was initiated in the emergency department for 68 patients (87.2%) and during cardiopulmonary resuscitation in eight patients (10.3%). Concurrent kidney replacement therapy was administered to 53 patients (67.9%). The median time from emergency department arrival to veno-arterial extracorporeal membrane oxygenation initiation was 1 h (IQR: 0.5-2.0 h), with a significant (P = 0.02) delay observed among survivors. The median duration of extracorporeal membrane oxygenation support was 48.0 h (IQR: 36.0-68.0 h), and the median intensive care unit stay was 6 days (IQR: 4-9 days). The overall survival with veno-arterial extracorporeal membrane oxygenation was 67.9% (n = 53), while 25 patients (32.1%) died despite this support. Among the 17 traceable patients who declined admission, the mortality was 100%. Complications related to extracorporeal membrane oxygenation occurred in 63 patients (80.8%), with 15 (19.2%) experiencing severe adverse events.
DISCUSSION: Our study has some limitations. It was a single-centre retrospective study, which limits the generalizability of the findings, and our data are prone to selection bias.
CONCLUSION: A retrospective study of 78 patients with aluminium phosphide poisoning who underwent veno-arterial extracorporeal membrane oxygenation was conducted in a single centre, and the overall survival was 67.9%. Veno-arterial extracorporeal membrane oxygenation offers temporary circulatory support during reversible myocardial depression with a high risk of complications. Further prospective, multicentre studies are warranted to refine indications, evaluate cost-effectiveness and assess long-term outcomes in aluminium phosphide poisoning.
参考来源
- Kumar A, Prakash J, Berwal K, et al. Real-world experience of veno-arterial extracorporeal membrane oxygenation in severe aluminium phosphide poisoning. Clin Toxicol (Phila). 2025. PMID: 40874872. doi:10.1080/15563650.2025.2544948
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。